Lorne Steinberg Wealth Management Inc. Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Lorne Steinberg Wealth Management Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,627 shares of the company’s stock after selling 747 shares during the quarter. Lorne Steinberg Wealth Management Inc.’s holdings in Johnson & Johnson were worth $2,763,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Community Bank & Trust Waco Texas lifted its position in shares of Johnson & Johnson by 1.7% during the fourth quarter. Community Bank & Trust Waco Texas now owns 56,485 shares of the company’s stock worth $8,853,000 after purchasing an additional 960 shares during the last quarter. Pacific Wealth Strategies Group Inc. raised its holdings in shares of Johnson & Johnson by 28.3% in the fourth quarter. Pacific Wealth Strategies Group Inc. now owns 2,403 shares of the company’s stock valued at $377,000 after acquiring an additional 530 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Johnson & Johnson by 7.0% in the fourth quarter. Parkside Financial Bank & Trust now owns 18,134 shares of the company’s stock valued at $2,842,000 after acquiring an additional 1,182 shares in the last quarter. SlateStone Wealth LLC raised its holdings in shares of Johnson & Johnson by 5.0% in the fourth quarter. SlateStone Wealth LLC now owns 38,719 shares of the company’s stock valued at $6,069,000 after acquiring an additional 1,831 shares in the last quarter. Finally, Monument Group Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $261,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. Royal Bank of Canada dropped their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Morgan Stanley lowered their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, April 15th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Finally, Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $175.86.

Johnson & Johnson Stock Down 0.5 %

NYSE JNJ opened at $146.14 on Monday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The business’s fifty day simple moving average is $155.26 and its 200-day simple moving average is $155.29. The firm has a market cap of $352.17 billion, a PE ratio of 9.11, a P/E/G ratio of 2.41 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.68 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.39%. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s payout ratio is 29.68%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.